Protalix BioTherapeutics (PLX) Inventory Average (2011 - 2026)

Protalix BioTherapeutics' Inventory Average history runs 15 years deep, the most recent figure standing at $28.1 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 37.92% year-over-year to $28.1 million in Q1 2026; TTM through Mar 2026 was $28.1 million, a 37.92% increase from a year earlier, with the FY2025 full-year figure at $23.5 million, up 16.59% from the prior year.
• Inventory Average rose to $28.1 million in Q1 2026 per PLX's latest filing, from $23.5 million in the prior quarter.
• Across five years, Inventory Average topped out at $28.1 million in Q1 2026 and bottomed at $15.5 million in Q3 2022.
• The 5-year median for Inventory Average is $20.3 million (2023), against an average of $19.9 million.
• Across the five-year window, Inventory Average slipped 8.01% in 2024 and surged 37.92% in 2026, its largest moves.
• Year by year, Inventory Average stood at $15.7 million in 2022, then grew by 29.53% to $20.3 million in 2023, then declined by 5.38% to $19.2 million in 2024, then gained by 22.22% to $23.5 million in 2025, then rose by 19.62% to $28.1 million in 2026.
• Per Business Quant, the three latest PLX Inventory Average figures stand at $28.1 million (Q1 2026), $23.5 million (Q4 2025), and $21.2 million (Q3 2025).